Expense Ratio Rating
10 /10
Expense Rating
10 /10
Market Score
10 /10
Category Score
5 /10
Market Size
10 /10
$VIMAX Alternatives
Different Funds
We found 8,161 US Stocks Mid-Cap Blend funds. Here they are ordered by FI Score.
- asftx
- Mutual Fund
- Bond
- High Yield Bond
Arrow Dynamic Income Fund Class C
Expenses: 2.47% (Better than 0% of similar funds)
This is a bad choice for a High Yield Bond Bond fund. See why »
- dgqax
- Mutual Fund
- Alternatives
- Short
AmericaFirst Defensive Growth Fund Class A
Expenses: 3.31% (Better than 0% of similar funds)
This is a bad choice for a Short Alternatives fund. See why »
- ekar
- ETF
- Sector Equity
- Consumer Cyclicals
Ideanomics Shares NextGen Vhcl andTchETF
Expenses: 0.95% (Better than 0% of similar funds)
This is a bad choice for a Consumer Cyclicals Sector Equity fund. See why »
- ukpsx
- Mutual Fund
- Alternatives
- Inverse
ProFunds UltraShort Japan Fund Service Class
Expenses: 2.78% (Better than 0% of similar funds)
This is a bad choice for a Inverse Alternatives fund. See why »
- leoox
- Mutual Fund
- Bond
- High Yield Bond
Lazard Enhanced Opportunities Portfolio Open Shares
Expenses: 2.83% (Better than 0% of similar funds)
This is a bad choice for a High Yield Bond Bond fund. See why »
- shpax
- Mutual Fund
- Sector Equity
- Healthcare
Saratoga Health & Biotechnology Portfolio Fund Class A
Expenses: 2.22% (Better than 0% of similar funds)
This is a bad choice for a Healthcare Sector Equity fund. See why »
- rycrx
- Mutual Fund
- Alternatives
- Real Estate
Rydex Real Estate Fund Class C
Expenses: 2.46% (Better than 0% of similar funds)
This is a bad choice for a Real Estate Alternatives fund. See why »
- asarx
- Mutual Fund
- Alternative
- Short
Asset Management Fund Ultra Short Mortgage Fund
Expenses: 1.40% (Better than 0% of similar funds)
This is a bad choice for a Short Alternative fund. See why »
- shpcx
- Mutual Fund
- Sector Equity
- Healthcare
Saratoga Health & Biotechnology Portfolio Fund Class C
Expenses: 2.83% (Better than 0% of similar funds)
This is a bad choice for a Healthcare Sector Equity fund. See why »